Cargando…
YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial
Background: YF-H-2015005, a novel CXCR4 antagonist, has been proven to increase the quantities of circulating hematopoietic stem cells (HSCs), which results in an adequate collection of HSCs in non-Hodgkin lymphoma (NHL) patients. Methods: This was a multicenter, double-blind, randomized (1:1), plac...
Autores principales: | Liu, Weiping, Li, Yufu, Wang, Quanshun, Su, Hang, Ding, Kaiyang, Shuang, Yuerong, Gao, Sujun, Zou, Dehui, Jing, Hongmei, Chai, Ye, Zhang, Yicheng, Liu, Lihong, Wang, Chunling, Liu, Hui, Lin, Jinying, Zhu, Haiyan, Yao, Chen, Yan, Xiaoyan, Shang, Meixia, Wang, Shufang, Chang, Fengyuan, Wang, Xiaopei, Zhu, Jun, Song, Yuqin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884449/ https://www.ncbi.nlm.nih.gov/pubmed/33604348 http://dx.doi.org/10.3389/fmed.2021.609116 |
Ejemplares similares
-
Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients
por: Liu, Weiping, et al.
Publicado: (2020) -
Fabrication of Au-Ag nanocage@NaYF(4)@NaYF(4):Yb,Er Core-Shell Hybrid and its Tunable Upconversion Enhancement
por: Chen, Xu, et al.
Publicado: (2017) -
Mortality of lymphoma and myeloma in China, 2004–2017: an observational study
por: Liu, Weiping, et al.
Publicado: (2019) -
Conditional survival and hazards of death for peripheral T-cell lymphomas
por: Gao, Hongye, et al.
Publicado: (2021) -
A Comparison of Clinical Prognostic Indices in Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with a Pegylated Liposomal Doxorubicin Combination Regimen in China
por: Gao, Hongye, et al.
Publicado: (2022)